100
Participants
Start Date
April 7, 2023
Primary Completion Date
April 30, 2029
Study Completion Date
April 30, 2029
monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease
"Monitoring:~* hemoglobin and ferritin levels~* transfusion or intravenous iron~* hospitalization for bleeding or thrombose~* digestive bleeding and/or another haemorrhagic accident~* severity of epistaxis~* quality of life"
NOT_YET_RECRUITING
CHU d'Angers, Angers
NOT_YET_RECRUITING
CHU de Bordeaux, Bordeaux
NOT_YET_RECRUITING
Hôpital Ambroise Paré, Boulogne-Billancourt
NOT_YET_RECRUITING
CHU de Caen Normandie, Caen
RECRUITING
CHU clermont-ferrand, Clermont-Ferrand
NOT_YET_RECRUITING
CHU de Dijon, Dijon
NOT_YET_RECRUITING
CHRU de Lille, Lille
NOT_YET_RECRUITING
Hospices Civiles de Lyon, Lyon
NOT_YET_RECRUITING
Assistance Publique - Hôpitaux de Marseille, Marseille
NOT_YET_RECRUITING
CHU de Montpellier, Montpellier
NOT_YET_RECRUITING
CHU de Nancy, Nancy
NOT_YET_RECRUITING
CHU de Nantes, Nantes
NOT_YET_RECRUITING
CHU de Nice, Nice
NOT_YET_RECRUITING
AP-HP - Hôpital Ténon, Paris
NOT_YET_RECRUITING
CHU de Poitiers, Poitiers
NOT_YET_RECRUITING
CHU de Rennes, Rennes
NOT_YET_RECRUITING
CHRU de Strasbourg, Strasbourg
NOT_YET_RECRUITING
CHU de Toulouse, Toulouse
University Hospital, Clermont-Ferrand
OTHER